Harvest Investment Services LLC Acquires New Holdings in Johnson & Johnson (NYSE:JNJ)

Harvest Investment Services LLC purchased a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,767 shares of the company's stock, valued at approximately $255,000.

Other institutional investors have also recently bought and sold shares of the company. MRP Capital Investments LLC boosted its holdings in Johnson & Johnson by 4.1% during the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock worth $237,000 after purchasing an additional 65 shares during the last quarter. Syverson Strege & Co increased its position in shares of Johnson & Johnson by 4.9% in the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock valued at $202,000 after acquiring an additional 65 shares during the last quarter. Werba Rubin Papier Wealth Management raised its holdings in Johnson & Johnson by 3.3% during the fourth quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company's stock worth $301,000 after acquiring an additional 66 shares in the last quarter. Denali Advisors LLC grew its stake in Johnson & Johnson by 1.3% in the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock valued at $742,000 after purchasing an additional 67 shares in the last quarter. Finally, Sage Mountain Advisors LLC increased its position in shares of Johnson & Johnson by 0.5% during the 4th quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock worth $2,106,000 after purchasing an additional 67 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

Analyst Ratings Changes

JNJ has been the topic of a number of recent analyst reports. Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Barclays dropped their target price on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Stifel Nicolaus reduced their price target on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a report on Thursday, January 23rd. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price objective for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Finally, Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $171.82.

Johnson & Johnson Trading Up 0.5 %

Shares of JNJ stock opened at $157.68 on Wednesday. The stock has a 50 day simple moving average of $159.54 and a 200 day simple moving average of $154.95. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a market cap of $379.98 billion, a P/E ratio of 23.71, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. On average, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.30%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.